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Objectives: Neutrophil influx is one of the first events in a formed deep venous thrombosis (DVT), but whether these cells
are active participants in the resolution process is not clear. This study tests the hypothesis that neutrophils (PMN) are
active participants in DVT resolution.
Methods: Thrombosis was induced by inferior vena caval (IVC) ligation in male Sprague-Dawley rats, and rats were
sacrificed at 2, 4, or 7 days for evaluation of the thrombus. Neutropenia was induced by rabbit anti-rat PMN serum, and
controls received rabbit serum. Venography was performed at the 7-day time point. Immunohistochemical staining was
performed to quantify intrathrombus PMNs and monocytes, and the myeloperoxidase (MPO) assay was performed to
assess intrathrombus neutrophil activity. Intrathrombus concentrations of kerotinocyte cytokine (KC), macrophage
inflammatory protein-2 (MIP-2),  interferon inducible protein-10 (IP-10), macrophage inflammatory protein-1 
(MIP-1), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor (TNF)– were quantified by
enzyme immunoassay at each time point and normalized to total protein. Total collagen was determined at day 7.
Results: Peripheral blood smears showed a 94% PMN reduction at 2 days (P <.05), recovering to 44% of control at 7 days.
Intrathrombus PMNs were significantly lower in neutropenic rats at 2 and 4 days, but there were no differences in
intrathrombus monocytes. The MPO assay confirmed reduced neutrophil activity at 4 days. Thrombi from neutropenic
rats were larger at 2 and 7 days compared with controls. In vivo thrombus area at 7 days as assessed by venography was
also greater in neutropenic rats as compared with controls. The intrathrombus KC concentration was increased more than
20-fold in the neutropenic rats at 2 days, but there were no significant differences in other intrathrombus chemokines.
Finally, intrathrombus collagen was increased over threefold in neutropenic rats as compared with controls.
Conclusion: Neutropenia impairs DVT resolution by several measures, most likely by altering normal fibrinolytic activity
and thrombus collagen turnover. (J Vasc Surg 2003;38:1090-8.)
Deep venous thrombosis (DVT) is a common condi-
tion affecting approximately 250,000 patients per year and
responsible for 50,000 deaths per year.1 Although antico-
agulant therapies are effective for prophylaxis and in pre-
venting thrombus propagation, the basic mechanisms of
DVT resolution have only recently become better under-
stood. Systemic neutropenia and deficits in neutrophil ac-
tivity are common effects of many diseases, such as chemo-
therapy-induced leukopenia and viral infections. These
patients are at higher risk of DVT, although the complete
mechanisms have not been delineated. A recent retrospec-
tive study has suggested that patients with malignancy and
recurrent leukopenic episodes are at increased risk of recur-
rent venous thromboembolic events.2
These clinical observations indirectly argue for the im-
portance of neutrophils (PMN) in clearance of thrombus.
Indeed, PMNs are associated with thrombus resolution, as
first demonstrated by Stewart,3 and explored in previous
studies from our group.4 A primary function of PMNs is in
modulating an inflammatory response by means of cyto-
kines, proteases, and reactive oxygen species. Although
PMNs may be prothrombotic at DVT initiation, their role
may be important for thrombolysis once it has formed,
through direct and indirect cellular mediators.5,6
Localization and activation of PMNs and other por-
tions of the cellular immune system are mediated by che-
mokines, which are chemotactic cytokines with varying
specificities and roles.7 Chemokines are classified on the
basis of the placement of four cysteine residues toward the
beginning of their protein sequence, and the best studied
are the CC and CXC subfamilies. The CXC chemokines are
divided into ELR and ELR subfamilies, on the basis of
the presence of a three amino acid sequence preceding the
CXC sequence. Of note, CXC ELR chemokines are
generally neutrophil-attractant and proangiogenic; inter-
leukin 8 (IL-8) is the prototypical member of this group.
Moreover, CXC chemokines may play a direct role in DVT
resolution in a murine model (unpublished data).
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Given the potential roles of inflammatory cells and
mediators in initiating and propagating venous thrombosis,
several anti-inflammatory approaches to limiting DVT for-
mation, such as P-selectin antagonism,8-10 anti–tumor ne-
crosis factor (TNF) antibody,8 and supplementation of
interleukin 10 (IL-10) by rIL-10 injection or local overex-
pression11,12 have been studied. These agents generally
have been administered before thrombus formation to
produce an anti-inflammatory milieu, with thrombus for-
mation subsequently attenuated. However, proinflamma-
tory states are beneficial in many settings of established
injury; indeed, inflammatory responses are an essential part
of wound healing.13,14 In a previous report, IL-8 supple-
mentation accelerated DVT resolution in the rat model,
but whether this was conferred by the chemokine itself or
the increased intrathrombus PMNs was not established.15
This study sought to determine whether PMNs play a
direct role in DVT resolution and whether PMN depletion
at the time of DVT genesis secondarily alters the local
leukocyte and chemokine environment.
METHODS
Study design and animal model. The study design is
summarized in Fig 1. Male Sprague-Dawley rats (350 to
450 g) were used for all studies. Thrombosis was induced in
a rat model that has been used successfully by our labora-
tory, and it is fully described elsewhere.8,9,11,12,15 Briefly,
the model consists of ligation of the inferior vena cava
(IVC) below the renal veins and of all visible side branches.
A clot develops in90% of rats. At sacrifice, a blood sample
was taken from the suprarenal IVC or left ventricle, and the
thrombosed IVC was carefully dissected and removed for
histologic and biochemical studies after thrombus-vein wall
separation, as follows. Thrombus weight was measured and
corrected for length of segment as described.8-12
Both neutropenic and control groups were studied at
each time point, and rats were sacrificed at 2, 4, or 7 days
thrombus induction. To induce systemic neutropenia, rats
allocated to neutropenia groups were given a 0.25-mL to
0.5-mL loading dose of rabbit anti-rat PMN serum (Accu-
rate Chemical, Westbury, Conn) by means of tail vein
injection the day before IVC ligation and 0.25-mL boost-
ers on the day of ligation and the day after ligation.16 Rats
allocated to control groups were given the same volumes of
rabbit serum at the same time points. Systemic neutropenia
was confirmed by analyzing a peripheral smear stained by
Diff-Quik (Jorgensen Laboratory, Loveland, Colo) at sac-
rifice, and random animals had venous blood sampled for
thrombin clotting time (TCT) and activated partial throm-
boplastin times (aPTT) per standard techniques.
All studies were approved by the University of Michi-
gan Committee on the Use and Care of Animals (UCUCA
#7916) and complied with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
Venography. Venography was performed by using a
BV29 C-arm fluoroscopy unit (Phillips Medical System,
Cincinnati, Ohio) with the image intensifier placed40 cm
above the table to provide adequate magnification. The rats
were positioned in the center of the field, and 1.5-mL
Hypaque solution (2.5-mL Hypaque with 1.5-mL saline)
per radiograph was injected into the tail vein. The subtrac-
tion mode was used to shoot the final images. The contrast
was visualized under real time to assure adequate filling of
the IVC. Anterior-posterior and lateral radiographs were
taken by rotating the animal and not the C-arm. The digital
venogram was then transferred onto a computer hard drive
by using the software Vidcap (Version 5.1; Seattle, Wash)
and then analyzed by using NIH Image 1.62, a public
domain program. The images had resolution of (250 pix-
els/cm) and were converted to TIFF format with Adobe
Photoshop (Adobe Systems, Inc, Seattle, Wash). Note that
the veterbrae of the animals were used to standardize the
thrombus measurements to allow intra-animal comparison
and that the measurements were quantified as millimeters
Fig 1. Study design. This chart details the sequence of rabbit anti-rat PMN serum (anti-PMN serum) or control rabbit
serum injection, IVC ligation, sacrifice, and the outcome measurements assessed in this study.
JOURNAL OF VASCULAR SURGERY
Volume 38, Number 5 Varma et al 1091
squared. Review of the images was done in a blinded
fashion.
Immunohistochemistry. The harvested proximal one
third of the thrombus, closest to the ligature, was consis-
tently used for histologic analysis. The IVC was imbedded
in paraffin, sliced into 10-m-thick sections, and staining
was performed as described.12,15 Briefly, the tissue was
deparaffinized and dehydrated through graded alcohols,
followed by blocking nonspecific binding sites with species-
specific serum. Neutrophils were localized with 1:1000
anti-PMN antibody (Accurate Chemical, Westbury,
Conn), and monocytes were localized with 1:100 ED-1
antibody (Serotec, Oxford, England). A rabbit kit was used
for the neutrophil staining, and a mouse kit was used for the
monocyte staining per manufacturer’s instructions (both
from Vector Laboratories, Burlingame, Calif). Slides were
counterstained with hematoxylin and cover slipped. For
analysis, five randomly chosen high-powered fields were
selected from near the vein wall–thrombus interface (as
most leukocytes are present in this area), and positive
staining cells were counted in a blinded fashion.
Myeloperoxidase (MPO) assay. Thrombus samples
were prepared with separation of the thrombus from the
vein wall, followed by homogenization, sonication (30 s),
and centrifugation (15 min at 10000 g) of the thrombus
in a buffer solution. The homogenate was then reacted with
o-dianisidine hydrochloride (Sigma, St. Louis, Mo), and
the reaction product was measured at 490 nm as de-
scribed.11 Results were reported as change in optical den-
sity per minute.
Enzyme-linked immunosorbent assays (ELISA).
ELISAs were performed as previously described for keroti-
nocyte cytokine (KC, a rodent IL-8 analogue), macro-
phage inflammatory protein-2 (MIP-2),  interferon in-
ducible protein-10 (IP-10), macrophage inflammatory
protein-1 (MIP-1), monocyte chemoattractant pro-
tein-1 (MCP-1), and tumor necrosis factor– (TNF-
).12,15,17 The thrombi were prepared in the same manner
as for the myeloperoxidase assay. Tissue homogenate
ELISAs were done with species-specific primary antibodies
quantified by using a double ligand technique. Plates were
read at 450 nm.
Total protein quantification was performed by a mod-
ified Bradford assay (Pierce, Inc, Rockford, Ill) per manu-
facturer’s instructions on the homogenate of each animal
sample used for ELISA, with serial dilutions of bovine
serum albumin as standards. Results were expressed as
pg/mg protein, to account for differing protein composi-
tions of samples.
Collagen assay (Sircol collagen assay). Thrombus
collagen content was estimated by a commercially available
kit according to manufacturer’s instructions (Bicolor LTD,
Belfast, North Ireland). This collagen assay uses a quanti-
tative method by which anionic sirius red (direct red) dye
binds to the side chains of basic amino acids found in
collagen. Total collagen is presented as g/mg thrombus.
Statistical analysis. All statistical analysis in this study
was performed by one-way analysis of variance or t test, and
data are reported as mean	 SEM. P
 .05 was considered
significant.
RESULTS
Rats treated with anti-PMN serum were neutro-
penic during thrombus formation and through sacri-
fice. To confirm the effects of the anti-PMN serum, pe-
ripheral blood smears were performed. A 94% reduction in
circulating PMNs was seen among neutropenic rats sacri-
ficed at 2 days compared with controls from the same time
point (control 21	 2 vs 1.4	 0.0% differential, P
 .05, N
 3), and a 44% reduction among neutropenic rats com-
pared with time-matched controls was seen at 7 days (con-
trol 32 	 7 vs 14 	 2% differential, P  .05, N  3). No
significant differences in peripheral monocyte counts were
observed. Lastly, thrombin clotting time and activated
partial thromboplastin time, as a measure of coagulability,
were not significantly different between control and anti-
PMN rats (control aPTT/TCT  36 	 4/28 	 4 vs
anti-PMN 32 	 5/22 	 2 seconds, P  .05, N  6).
Immunohistochemical staining was used to localize
PMNs and monocytes in the thrombus. The number of
PMNs detectable in the thrombus was over 51% lower in
rats treated with anti-PMN serum rats at 2 days (18.2 	 6
vs 37.4 	 6.5 cells/5 hpf, N  5; P 
 .01) and over 41%
lower at 4 days (23 	 9 vs 39 	 4 cells/5 hpf, N  5; P

.01) compared with controls at those time periods. The
difference between anti-PMN and control PMN counts
(15.4 	 4.2 vs 18.4 	 6.2, N  4) rats at 7 days was not
significant, with a noted decrement in intrathrombus PMN
content but none in the anti-PMN rat thrombi (Figs 2, A
and 3). There was no difference in the number of intrath-
rombus monocytes detectable at 2, 4, or 7 days among rats
treated with anti-PMN serum (N 4) (Fig 2, B). The MPO
activity reflects PMN function as measured by enzyme
activity, and it indirectly measures PMN content. No sig-
nificant difference was observed at the 2-day time point (N
 3), whereas a significant reduction in activity was ob-
served at the 4-day time point (13	 7 vs 36	 2 U activity,
n  3; P 
 .05) (Fig 2, C).
Thrombus size was larger in neutropenic rats.
Thrombus size was measured at sacrifice as a gross measure
of thrombus resolution. It is assessed by calculating the
weight/length ratio, which reflects the density of the
thrombus, accounts for variations in the length of vein
recovered at sacrifice, and has been consistent in reflecting
thrombus dissolution.8,9,11,12,15 Weight/length ratios of
thrombi from neutropenic animals harvested at 2 days (147
	 12 vs 94	 10 mg/cm, n 6; P
 .05) and 7 days (168
	 71 vs 121 	 18 mg/cm, n  6; P 
 .05) were signifi-
cantly larger than control animals’ thrombi (Fig 4). This
effect was lost among animals sacrificed at 4 days, with
control rats having a weight/length ratio of 128 	 14
mg/cm and neutropenic rats having a weight/length ratio
of 106 	 9 mg/cm (N  6, P  .20).
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Thrombus area in vivo is increased in neutropenic
rats. To corroborate the findings of increased thrombus
size at harvest, venography was performed to allow assess-
ment of intrathrombus area in two dimensions at 7 days.
Representative venograms are shown in Fig 5, which
reflects the increased in vivo thrombus area in neutro-
penic rats. The mean area was 10.4 	 1.3 mm2 in the
control rats and 19.1	 2.6 mm2 among the neutropenic
Fig 2. The inflammatory response within the thrombus was assessed by immunohistochemical staining for (A) PMNs
and (B) monocytes, as well as the (C) MPO assay. (A) There were significantly fewer intrathrombus PMNs in
neutropenic rats at 2 and 4 days (both P 
 .05), but no difference at 7 days. (B) There were no differences in
intrathrombus monocytes among any groups. (C) There was significantly less MPO activity among 4-day neutropenic
rats compared with 4-day controls, but no differences were detectable at other time points.
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rats (P 
 .05, N  5-7), which reflects an increased area
of occlusion within the same region of interest analyzed
at 7 days.
Intrathrombus KC concentration is greater in neu-
tropenic rats. As chemokines are involved with directing
leukocytes to areas of inflammation as well as inducing
intrinsic leukocyte activity, common CXC and CC chemo-
kines in control and neutropenic rats were analyzed. Che-
mokines may be produced by infiltrating leukocytes as well
as resident vein wall cells. Intrathrombus KC concentration
was nearly 20-fold higher at 2 days in neutropenic rats as
compared with controls (200 	 87 vs 8.9 	 8 ng/mg
protein, N  5, P 
 .05). The cytokines TNF-, MIP-2,
and IP-10 were all present in very low amounts (
50-
pg/mg protein) in both groups (N  4 each). Two CC
chemokines, MIP-1 and MCP-1 showed no significant
differences at 2 or 7 days between the treatment groups (N
 4, P  .10). However, 4-day thrombus MIP-1 was
2.3-fold higher in controls as compared with anti-PMN rats
(277 	 61 vs 118 	 56 pg/mg protein, N  8, P  .08).
More significantly, 4-day MCP-1 was twofold higher in
control thrombi than anti-PMN treated rats (89	 21 vs 34
	 7 pg/mg protein, N  8, P  .02).
Neutropenic rat thrombi have increased fibrosi-
s. As the thrombus matures, acute phase collagen turnover is
apparent.18 Total collagen within the thrombus was measured
to assess the extent of fibrosis remaining within the thrombus
at 7 days. There was 3.3-fold greater collagen in the neutro-
penic rat thrombi as compared with controls (P
 .05; N 5,
Fig 6, A), which suggests impaired collagen turnover in the
neutropenic rats. Trichrome staining of the thrombus sections
shows intrathrombus collagen (Fig 6, B,C).
Fig 3. Representative immunohistochemical staining of thrombi from (A) control and (B) neutropenic rats (200).
There are far fewer PMNs visible within the thrombi of neutropenic rats.
Fig 4. Thrombus size. Neutropenic rats had thrombi with larger weight/length ratios at 2 days and 7 days (P
 .05),
but there was no difference in thrombus size at 4 days.
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DISCUSSION
This study confirms the important role of PMNs on
DVT resolution, which previously in vivo has only been
associative,3 as neutropenic rats had larger thrombus size
and in vivo area as well as increased fibrosis. The impaired
thrombus resolution in neutropenic rats was likely solely
caused by the PMN, as peripheral and thrombus monocyte
(ED-1) counts were similar between groups. No differ-
ences in baseline clotting times were observed, which ar-
gues against a systemic effect of the anti-PMN serum.
Moreover, it was unlikely caused by alterations in common
chemokines, as only KC (a primary CXC chemokine with
PMN chemoattractant activity) was increased in the neu-
tropenic rats. This finding also indirectly suggests that KC,
which has in vitro proangiogenic activity, did not accelerate
thrombus resolution outside of PMN recruitment and per-
haps activation. This finding also broadens prior work,
whereby IL-8 supplementation significantly enhanced
DVT resolution in the same rat model and was associated
with increased intrathrombus PMNs.15 Moreover, IL-8
supplementation in the setting of PMN depletion in the rat
model of DVT did not reverse the impaired resolution
(unpublished observations). Taken together, these obser-
vations suggest the PMN is an early primary cellular effector
of DVT dissolution. However, it is also possible because
PMN was depleted at the time of thrombus generation that
the thrombus composition might be entirely different.
However, the basic gross histology was not markedly dif-
ferent and monocytes (ED-1 cells) were not significantly
fewer.
The finding that intrathrombus PMNs were signifi-
cantly decreased as compared with controls but 2-day MPO
was not as greatly reduced suggests that those PMNs within
the thrombus of the neutropenic rats may have been max-
imally activated by the increased chemokine KC. However,
although the 2-day neutropenic rat’s intrathrombus PMNs
may have been activated, it does not necessarily follow that
this activity is reflected as DVT resolution. Chemokines are
known to have PMN actions beyond simply chemoattrac-
tant activity.7,14,17 A paradoxical increase in KC with neu-
trophil depletion has previously been shown for KC mRNA
expression in abdominal wounds14 and in KC protein levels
in a CXCR2 deletion mouse model of cerebral abscess and
DVT19 (unpublished data). Neutrophil depletion seemed
only to alter the CC chemokines MCP-1 and MIP-1 at
day 4, although thrombus monocyte influx was not im-
paired. It is speculated that as the thrombi had fewer
PMNs, it may be that certain mediator interactions be-
tween the thrombus and vein wall were altered and suggests
the interplay of surrounding vein wall and other leukocyte
subtypes. How this decrease in these two CC chemokines
may have impaired monocyte function is unknown.
One potential mechanism to explain why PMN deple-
tion impairs DVT resolution includes loss of natural early
fibrinolytic activity, and the larger thrombi in the PMN-
depleted rats supports this, although it may be biphasic, as
the 4-day thrombi were not significantly different in size.
Alternatively, the early influx of PMNs may be important
for fostering thrombus matrix changes that mediate activity
of other leukocytes. For example, the PMNs may favorably
alter the thrombus matrix for monocyte release of angio-
genic mediators.20 Neutrophils release a plasminogen acti-
vator (PA), separate from known PAs such as tissue plas-
minogen activator.6 Recent work for Moir and colleagues
has shown in an in vitro system that PMNs mediate endog-
enous spontaneous fibrinolysis probably via urokinase
PA.21 PA inhibitor-1 (PAI-1) is the principal inhibitor for
several PAs, and PAI-1 is degraded by neutrophil elastase.22
Additionally, the plasmin inhibitor, 2-antiplasmin, is oxi-
dized and inactivated by PMNs.23 Taken together, it is
likely that the PMN contributes to early DVT resolution by
direct and indirect promotion of a fibrinolytic environ-
ment. Lastly, there is no data in the literature to support the
notion that PMNs that release more MPO (eg, in the 2-day
anti-PMN treated rats) are more active with regard to
fibrinolysis in contrast to the known indirect fibrinolytic
activity of elastase.22
A second possible mechanism that could explain im-
paired DVT resolution in neutropenic rats may be impaired
thrombus neovascularization. Thrombus neovasculariza-
tion has been tightly associated with DVT resolution in
both humans and rodent models.15,24,25 Neutrophils pro-
Fig 5. Venograms from (A) control and (B) neutropenic rats taken at 7-days post-IVC ligation. (A) The thrombus of
the control rats had greater recanalization, and less IVC thrombus area, which was not seen in the neutropenic rats (B),
where larger IVC thrombus area and more extensive collateral formation was seen.
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duce angiogenic mediators, such as vascular endothelial
growth factor,26 and a proangiogenic milieu is found in
resolving thrombi.27 Previous studies by our group have
shown that the proinflammatory cytokine IL-8 accelerates
DVT resolution and was associated with increased neovas-
cular channel formation, as estimated by thrombus colloi-
dal carbon staining and laminin immunohistochemical
staining of neovascular channels.15,25 It is likely that the
thrombus neovascularization that forms is most important
for allowing influx of later inflammatory cells such as mono-
cytes rather than providing for substantial prograde venous
flow. Venography is not sensitive enough to delineate
microvascular channels but did show that venous collateral
formation was not dependent on PMNs, although these
channels represent small lumbar vessels that dilate and do
not require de novo formation from biochemical media-
tors. Indeed, neutropenic rats had larger and more persis-
tent collaterals, which shows that the thrombus burden was
physiologically significant as well. Further studies on the
determinants of the angiogenic aspects of thrombus reso-
lution are likely to clarify the role(s) of PMNs in this
process.
An interesting finding was the increased thrombus
fibrosis in the neutropenic rats. This suggests that the PMN
A
Fig 6. A, Sircol collagen assay. There was significantly more collagen (types I to III) remaining in the thrombi of
neutropenic rats compared with controls at 7 days. This is reflected in Trichrome-stained section (100) from (B)
control and (C) neutropenic rat thrombi. Note increased fibrosis within the thrombus proper as well as the vein wall in
the neutropenic IVC section, stained whitish-blue. Clot is red color. T  thrombus. W  vein wall.
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is important for the normal breakdown of early wound
collagen in the thrombus, similar to a nonluminal wound.
In all acute processes, type III collagen is laid down as a
provisional matrix for influx of structural cells and leuko-
cytes.13 Neutrophils release collagenases, such as matrix
metalloproteinases 8 and 9, that actively degrade collagen
in addition to their activity of plasminogen activation.28
Neutrophils also secrete elastase with collagenolytic activi-
ty.23 Interestingly, our prior work with IL-8 supplementa-
tion showed increased thrombus fibrosis, but the assay used
in that study was not as sensitive as the one in the current
study. In addition, the possibility that stimulating PMNs
with an exogenous chemokine may increase reactive oxy-
gen species production exists.7,15
As the most common white blood cells and the princi-
pal cellular effector of the early inflammatory response,
PMNs are essential to resolution of many physiologic in-
sults. Neutrophil depletion has been studied in a wide
variety of models of injury, including angioplasty-induced
arterial injury,29 abdominal wounds,30 cerebral infection,19
and reperfusion injury,31 to name a few. Most of these
studies have indicated that PMNs cause damage in these
modeled clinical settings, but it really depends on the
clinical situation to determine when PMNs are detrimental.
Neutropenia is a common clinical sequelae of disease and
certain therapeutic medications. PMNs are often depleted
in patients with cancer, and neutrophil chemotaxis has been
shown to be impaired in vitro in patients with shock.29 In
the setting of malignancy, the incidence of DVT is in-
creased as well and Lin et al have shown a significant
association between increasing number of leukopenic epi-
sodes and recurrence of DVT in cancer patients.2 Although
several other factors affect the incidence of DVT in cancer
patients, including the type of cancer and the chemothera-
peutic regimen, this correlation suggests that in the dy-
namic setting of thrombus formation and resolution, leu-
kopenia may decrease the host’s natural thrombus
resolution capability. Thus, asymptomatic DVT that nor-
mally would have resolved have a higher likelihood of
becoming symptomatic in these patients.
This work has shown that PMNs contribute to early
DVT resolution, which suggests an important role for a
proinflammatory environment. Further experimental work
will define the mechanisms of the PMNs and monocytes on
in vivo thrombolytic and angiogenic activity, to allow po-
tential pharmacologic targets for therapy without the haz-
ards of anticoagulation.
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